Published in Brain Res on July 26, 1991
Spatial memory is enhanced in long-living Ames dwarf mice and maintained following kainic acid induced neurodegeneration. Mech Ageing Dev (2010) 0.90
Distinct roles of basal forebrain cholinergic neurons in spatial and object recognition memory. Sci Rep (2015) 0.80
Organization of food protection behavior is differentially influenced by 192 IgG-saporin lesions of either the medial septum or the nucleus basalis magnocellularis. Brain Res (2008) 0.76
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci (1997) 3.61
Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology (1997) 3.53
Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci (2000) 3.40
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology (2003) 3.07
Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol (1992) 3.04
A validation study of the Dementia Questionnaire. Arch Neurol (1994) 2.89
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology (2000) 2.76
Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci (1988) 2.73
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol (2000) 2.37
In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology (2007) 2.24
Acute ascending necrotizing myelopathy caused by herpes simplex virus type 2. Neurology (1987) 2.11
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology (2000) 2.10
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology (1998) 1.96
Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology (2000) 1.91
Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol (1994) 1.90
The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology (2004) 1.87
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature (1993) 1.85
Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.80
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology (2008) 1.80
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology (2004) 1.74
Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology (2002) 1.74
Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol (2000) 1.69
Essential role of neocortical acetylcholine in spatial memory. Nature (1995) 1.68
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2007) 1.67
Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol Aging (1999) 1.66
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology (1996) 1.64
Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 1.58
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology (1997) 1.58
Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch Neurol (1999) 1.56
Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. Neurology (2002) 1.55
Monitoring progression in Alzheimer's disease. J Am Geriatr Soc (1991) 1.55
The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Arch Neurol (1990) 1.55
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.53
Intraparenchymal infusions of 192 IgG-saporin: development of a method for selective and discrete lesioning of cholinergic basal forebrain nuclei. J Neurosci Methods (1999) 1.52
Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology (2002) 1.49
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology (2007) 1.48
Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology (1995) 1.42
Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology (2003) 1.42
Parkinson's disease. The possible relationship of laterality to dementia and neurochemical findings. Arch Neurol (1984) 1.39
Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology (1990) 1.38
A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.36
Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn (1996) 1.36
Hippocampal sclerosis contributes to dementia in the elderly. Neurology (1997) 1.34
A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res (1985) 1.33
Alzheimer's disease: a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam. Neurology (1986) 1.28
Diagnostic validity of the dementia questionnaire for Alzheimer disease. Arch Neurol (1998) 1.22
Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. Neurology (2007) 1.22
Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol (1995) 1.22
Assessment of agitation in Alzheimer's disease: the agitated behavior in dementia scale. Alzheimer's Disease Cooperative Study. J Am Geriatr Soc (1999) 1.22
Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J Neurosci (1994) 1.22
Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology (1985) 1.21
Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem (1998) 1.18
Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample. Arch Neurol (1995) 1.18
Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol (2000) 1.15
Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology (1996) 1.14
Death certificate reporting of dementia and mortality in an Alzheimer's disease research center cohort. J Am Geriatr Soc (1995) 1.14
Diagnosis and evaluation of dementia. Neurology (1995) 1.13
Abnormal verbal event related potentials in mild cognitive impairment and incipient Alzheimer's disease. J Neurol Neurosurg Psychiatry (2002) 1.13
Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.12
Comparison of the serial position effect in very mild Alzheimer's disease, mild Alzheimer's disease, and amnesia associated with electroconvulsive therapy. J Int Neuropsychol Soc (2000) 1.11
Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (1989) 1.11
Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol (1998) 1.10
Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Ann Neurol (1988) 1.09
Distinguishing normal and demented elderly with the selective reminding test. J Clin Exp Neuropsychol (1989) 1.08
Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology (2003) 1.05
Mini-Mental State Examination and Mattis Dementia Rating Scale performance differs in Hispanic and non-Hispanic Alzheimer's disease patients. J Int Neuropsychol Soc (1999) 1.05
Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol (1983) 1.05
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol (2003) 1.04
Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease. Neurology (1993) 1.03
Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia. J Am Geriatr Soc (1993) 1.03
Functional analysis of brain dopamine systems in a genetic mouse model of Lesch-Nyhan syndrome. J Pharmacol Exp Ther (1992) 1.03
Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study. Neurology (1999) 1.02
Learning and memory in rape victims with posttraumatic stress disorder. Am J Psychiatry (1998) 1.01
Anosmia is very common in the Lewy body variant of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 0.99
Therapeutic trials using tacrine and other cholinesterase inhibitors. Adv Neurol (1990) 0.98
Differentiation of Alzheimer's disease and Huntington's disease with the Dementia Rating Scale. Arch Neurol (1989) 0.96
The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease. Neurology (1994) 0.96
Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Ann Neurol (1996) 0.96
Cognitive deficits of patients with Alzheimer's disease with and without delusions. Am J Psychiatry (1992) 0.95
Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann Neurol (1997) 0.95
Solvent effects on beta protein toxicity in vivo. Neurobiol Aging (1993) 0.94
Plasma physostigmine concentrations after oral administration. Lancet (1985) 0.94
Attentional dysfunction associated with posttraumatic stress disorder among rape survivors. Clin Neuropsychol (2000) 0.94
Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. Neurobiol Aging (2000) 0.93
Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. Clin Sci (Lond) (1994) 0.91
Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Dis Assoc Disord (1996) 0.91
Excitotoxic cytopathology, progression, and reversibility of thiamine deficiency-induced diencephalic lesions. J Neuropathol Exp Neurol (1995) 0.91
Qualifying change: a method for defining clinically meaningful outcomes of change score computation. J Am Geriatr Soc (2000) 0.91
Cholinergic strategies for Alzheimer's disease. J Mol Med (Berl) (1998) 0.90
The Spanish Instrument Protocol: design and implementation of a study to evaluate treatment efficacy Instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 0.90
Alzheimer disease without neocortical neurofibrillary tangles: "a second look". Neurology (2004) 0.90
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology (2000) 0.89